Akeso Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Akeso şirketinin toplam hissedar öz sermayesi CN¥6.8B ve toplam borcu CN¥3.9B olup, bu da borç-öz sermaye oranını 58.4% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla CN¥12.8B ve CN¥6.0B dir.

Anahtar bilgiler

58.36%

Borç/özkaynak oranı

CN¥3.94b

Borç

Faiz karşılama oranı	n/a
Nakit	CN¥7.35b
Eşitlik	CN¥6.75b
Toplam yükümlülükler	CN¥6.00b
Toplam varlıklar	CN¥12.75b

Son finansal sağlık güncellemeleri

Güncelleme yok

Recent updates

Akeso, Inc.'s (HKG:9926) Shares Climb 29% But Its Business Is Yet to Catch Up

May 07

Earnings Update: Here's Why Analysts Just Lifted Their Akeso, Inc. (HKG:9926) Price Target To HK$104

May 03

Cadonilimab And Ivonescimab Trials Will Broaden Market Access

Apr 06 Akeso's strategic focus on bispecific antibodies and NRDL inclusion could drive significant revenue growth and expand market access.

Earnings Update: Here's Why Analysts Just Lifted Their Akeso, Inc. (HKG:9926) Price Target To HK$82.91

Apr 01

Akeso, Inc.'s (HKG:9926) Shares Climb 28% But Its Business Is Yet to Catch Up

Mar 16

Optimistic Investors Push Akeso, Inc. (HKG:9926) Shares Up 27% But Growth Is Lacking

Sep 09

Akeso, Inc. Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected

Aug 30

Akeso, Inc.'s (HKG:9926) CEO Compensation Is Looking A Bit Stretched At The Moment

Jun 24

Little Excitement Around Akeso, Inc.'s (HKG:9926) Revenues As Shares Take 25% Pounding

Jun 19

Are Investors Undervaluing Akeso, Inc. (HKG:9926) By 43%?

May 31

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 9926 'nin kısa vadeli varlıkları ( CN¥8.7B ) kısa vadeli yükümlülüklerini ( CN¥1.7B ) aşıyor.

Uzun Vadeli Yükümlülükler: 9926 şirketinin kısa vadeli varlıkları ( CN¥8.7B ) uzun vadeli yükümlülüklerini ( CN¥4.3B ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 9926 şirketinin toplam borcundan daha fazla nakiti var.

Borcun Azaltılması: 9926 'nin borç/öz sermaye oranı son 5 yılda 607.7% seviyesinden 58.4% seviyesine düştü.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: 9926 şirketinin mevcut serbest nakit akışına dayanarak yeterli nakit pistine sahip olup olmadığını belirlemek için yeterli veri yok.

Tahmini Nakit Akışı: 9926 tarihsel oranlara göre serbest nakit akışı büyümeye veya küçülmeye devam ederse yeterli nakit pistine sahip olup olmadığını belirlemek için yeterli veri yok.

Sağlıklı şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2025/05/23 05:34
Gün Sonu Hisse Fiyatı	2025/05/23 00:00
Kazançlar	2024/12/31
Yıllık Kazançlar	2024/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Akeso, Inc. 37 Bu analistlerden 20, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Shun Kei Law	CCB International Securities Limited
Zhishun Siu	CCB International Securities Limited
Yolanda Yin	CGS International

Akeso Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Recent updates

Akeso, Inc.'s (HKG:9926) Shares Climb 29% But Its Business Is Yet to Catch Up

Earnings Update: Here's Why Analysts Just Lifted Their Akeso, Inc. (HKG:9926) Price Target To HK$104

Full year 2024 earnings: EPS and revenues miss analyst expectations

Now 28% undervalued

Akeso, Inc. Announces Its Globally First-In-Class PD-1/VEGF Bispecific Antibody, Ivonescimab, Received Approval from the National Medical Products Administration

Akeso, Inc. Announces FDA Approval for Penpulimab-kcqx in Two BLA Indications for Comprehensive Treatment of Advanced Nasopharyngeal Carcinoma

Summit Therapeutics Inc. Announces Phase Iii Clinical Trial, Harmoni-6

Akeso's Ebdarokimab Receives Marketing Approval from the National Medical Products Administration

New minor risk - Share price stability

Cadonilimab And Ivonescimab Trials Will Broaden Market Access

Earnings Update: Here's Why Analysts Just Lifted Their Akeso, Inc. (HKG:9926) Price Target To HK$82.91

Full year 2024 earnings released: CN¥0.60 loss per share (vs CN¥2.42 profit in FY 2023)

Akeso, Inc. to Report Fiscal Year 2024 Results on Mar 30, 2025

Akeso's Penpulimab Receives NMPA Approval for First-Line Treatment of Nasopharyngeal Cancer

Akeso, Inc.'s (HKG:9926) Shares Climb 28% But Its Business Is Yet to Catch Up

Akeso, Inc. Announces the Publication of Its Phase III Clinical Trial Results for Ivonescimab in Head-to-Head Comparison with Pembrolizumab in The Lancet

Akeso Announces Completion of Patient Enrollment in the Phase III Clinical Trial of Cadonilimab for Adjuvant Treatment of High-Risk Recurrent Hepatocellular Carcinoma

Akeso, Inc. Announces First ADC Drug Clinical Trial, Marking a New Era for "IO 2.0 + ADC" Strategy

Akeso, Inc. Enrolles First Patient in The Phase III Clinical Trial of Ivonescimab in Combination with Chemotherapy for First-Line Treatment of Triple-Negative Breast Cancer

Akeso, Inc. Announces IND Acceptance for AK139, a Bispecific Antibody Targeting IL-4Ra and ST2 for Respiratory and Skin Diseases

Akeso, Inc. Announces Enrollment of First Patient in Phase 3 Trial of Cadonilimab for Consolidation Therapy After Current or Sequential Chemoradiotherapy in NSCLC

Akeso, Inc. Announces the Completion of Patient Enrollment in the Phase III Clinical Trial (HARMONi-6) Comparing Ivonescimab

Akeso, Inc.'s Gumokimab Monoclonal Antibody (IL-17) New Drug Application for the Treatment of Moderate to Severe Psoriasis Accept by NMPA

Akeso, Inc. Publishes Results for Cadonilimab (PD-1/CTLA-4) Phase III Data for First Line Treatment of Advanced Gastric Cancer

Co-Founder recently sold HK$214m worth of stock

Akeso Announces the Inclusion in China's National Reimbursement Drug List of Cadonilimab and Ivonescimab

Akeso, Inc.'s Penpulimab Combination Therapy for First-Line Treatment of Hepatocellular Carcinoma Accepted by NMPA

Akeso, Inc. Publishes Mechanism of Action for CLDN18.2/CD47 Bispecific Antibody AK132 for the First Time at SITC Annual Meeting

Akeso Announces First Patient Enrollment in Phase 3 Trial of Ivonescimab Combined with Ligufalimab (CD47) for First-Line Treatment of Head and Neck Squamous Cell Carcinoma (HNSCC), Compared to Pembrolizumab

Akeso, Inc. has completed a Follow-on Equity Offering in the amount of HKD 1.942576 billion.

Akeso Biopharma Announces Positive Results in Progression-Free Survival (PFS) and Overall Survival (OS) from Its Phase 3 Clinical Study

First half 2024 earnings released: CN¥0.28 loss per share (vs CN¥3.02 profit in 1H 2023)

Akeso's Cadonilimab Receives Second Indication Approval from NMPA for First-Line Treatment of Gastric/GEJ Cancer in All-Comers Population

Akeso, Inc. Secures Approval from China’s National Medical Products Administration for Ebronucimab, Expanding Treatment Options for Hypercholesterolemia

Akeso's Ivonescimab Plus Chemo in First-Line Triple-negative Breast Cancer Showed Promising Preliminary Efficacy and Good Safety At ESMO 2024

Optimistic Investors Push Akeso, Inc. (HKG:9926) Shares Up 27% But Growth Is Lacking

Consensus EPS estimates upgraded to CN¥0.43 loss

Akeso, Inc. Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected

First half 2024 earnings released: CN¥0.28 loss per share (vs CN¥3.02 profit in 1H 2023)

Akeso, Inc. to Report Q2, 2024 Results on Aug 28, 2024

Akeso, Inc. Announces Ivonescimab (Pd-1/Vegf) Received Priority Review from China's Nmpa for First-Line Treatment of Pd-L1 Positive Nsclc

Akeso, Inc. Announces That the First Patient Enrolled in the US Phase 2 Combination Therapy of it's Ligufalimab with Azacitidine for Myelodysplastic Syndrome

Akeso's Sbla for Ivonescimab in 1L Treatment of Pd-L1 Positive Nsclc Accepted by NMPA

Akeso, Inc. Announces Appointment of Bing C. Wang as Chief Financial Officer

New major risk - Share price stability

Akeso, Inc. Announces Change of Directors

Akeso, Inc.'s (HKG:9926) CEO Compensation Is Looking A Bit Stretched At The Moment

Little Excitement Around Akeso, Inc.'s (HKG:9926) Revenues As Shares Take 25% Pounding

Akeso, Inc., Annual General Meeting, Jun 30, 2024

Akeso, Inc. Announces Phase III Clinical Trial, Harmoni-2 or AK112-303 Met Its Primary Endpoint of Progression-Free Survival

Are Investors Undervaluing Akeso, Inc. (HKG:9926) By 43%?

New minor risk - Share price stability

Akeso, Inc. Receives NMPA's Marketing Approval in China for Ivonescimab Injection

Investor sentiment deteriorates as stock falls 24%

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

National Medical Products Administration Accepted the Supplemental New Drug Application by Akeso, Inc. for (Cadonilimab, Pd-1/Ctla-4) as First-Line Treatment for Cervical Cancer

New minor risk - Shareholder dilution

Akeso, Inc. has completed a Follow-on Equity Offering in the amount of HKD 1.18172 billion.

Akeso, Inc. has filed a Follow-on Equity Offering in the amount of HKD 1.18172 billion.

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Investor sentiment improves as stock rises 15%

Akeso, Inc. to Report Fiscal Year 2023 Results on Mar 18, 2024

Akeso Announces the First Patient Dosed in Phase III Trial of Cadonilimab(PD-1/CTLA-4) Combined with Chemotherapy versus Tislelizumab Combined with Chemotherapy in First-Line Treatment of PD-L1 negative NSCLC

Akeso Presents Promising Results of Cadonilimab and Lenvatinib in Combination with TACE in uHCC at 2024 ASCO GI

Akeso, Inc. Announces Innovative Clinical Development Roadmap

Akeso, Inc. Announces National Medical Products Administration Accepts the Supplemental New Drug Application for Kai Tan Ni (Cadonilimab, PD-1/CTLA-4) in Combination with Chemotherapy as First-Line Treatment for Gastric Cancer

Akeso, Inc. Publishes Results from CD47 Antibody Ligufalimab in Combination with Azacitidine for Newly Diagnosed Higher-Risk Myelodysplastic Syndrome and Treatment-nave Acute Myeloid Leukemia at ASH 2023

Akeso Publishes Results from Three Investigator-Initiated Trials

Founder recently sold HK$96m worth of stock

Akeso (9926. Hk) Announces AK104-303 Phase III Trial Meets One of its Primary Endpoints of Progression-Free Survival (PFS) for First-Line Treatment of Recurrent/Metastatic Cervical Cancer

Akeso, Inc. Announces AK104-303, A Phase III Trial of Cadonilimab Reached Progression-Free-Survival Primary Endpoint At Interim Analysis for First Line Treatment of Cervical Cancer

Akeso's Cadonilimab (PD-1/CTLA-4) Phase III Trial Meets Primary Endpoint at Interim Analysis Demonstrating Strong Overall Survival Benefit as First-line Treatment in All-comer Patients with Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GEJC)

Co-Founder recently sold HK$4.4m worth of stock

Investor sentiment improves as stock rises 17%

Akeso Announces Results of Phase Ib Clinical Trial for PD-1/VEGF Bispecific Antibody